In addition, we highlighted several drugs targeting genes that increase the risk of POAG, most likely through affecting VCDR, independent of IOP (without an apparent effect on IOP; Table 1): for example, CHEK2, encoding a cell cycle regulator and putative tumor suppressor; RPE65, which encodes retinoid isomerohydrolase, a component of the vitamin A visual cycle in retinal rod and cone photoreceptors14; and TNFSF13B, which encodes a tumor necrosis factor ligand family. This evidence concerns the gene TNFSF13B and open-angle glaucoma.